This suggested that the therapeutic effect of PAD on ROUs might be achieved by upregulating the protein expression of occludin, ZO-1, and claudin-1, as well as, increasing the content of the immune index SIgA, to improve the protection of the intestinal barrier in rats. The gene discussed is CLDN1; the disease is peripheral arterial disease.